Gibney Anthony S's Form 4 filing
Aura Biosciences, Inc. (AURA) · filed May 20, 2025
- Accession no.
- 0000950170-25-075403
- Filed
- May 20, 2025
- Trade date
- May 16, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $245.0K. Open-market sales total $7.82K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibney Anthony SCIK 0001750132 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2025 | Common Stock | PPurchaseAcquired | +50,000 | $4.90 | +$245,000 | 58,452 | Direct | |
| May 16, 2025 | Common Stock | SSaleDisposed | −1,519 | $5.15 | −$7,822.85 | 56,933 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2025 | Common Stock | PPurchaseAcquired | +12,500 | –F1 | – | 12,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On May 16, 2025, the Reporting Person purchased 50,000 shares of the Issuer's common stock and a warrant to purchase 12,500 shares of the Issuer's common stock at a purchase price of $4.90 in an underwritten public offering.
Referenced by the price of 1 transaction in Table II.
Remarks
Chief Financial and Business Officer